

Appendix B, Table 8. Characteristics of the CCR5 Antagonist (Last updated December 18, 2019; last reviewed December 18, 2019)

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations ^a	Serum Half-Life	Elimination/Metabolic Pathway	Adverse Events ^b
Maraviroc (MVC) <i>Selzentry</i>	Selzentry: • 150 and 300 mg tablets	Selzentry: • MVC 150 mg PO twice daily when given with drugs that are strong CYP3A inhibitors (with or without CYP3A inducers), including PIs (except TPV/r) • MVC 300 mg PO twice daily when given with NRTIs, T-20, TPV/r, NVP, RAL, and other drugs that are not strong CYP3A inhibitors or inducers • MVC 600 mg PO twice daily when given with drugs that are CYP3A inducers, including EFV, ETR, etc. (without a CYP3A inhibitor) Take MVC without regard to meals.	14–18 hours	CYP3A4 substrate	Abdominal pain Cough Dizziness Musculoskeletal symptoms Pyrexia Rash Upper respiratory tract infections Hepatotoxicity, which may be preceded by severe rash or other signs of systemic allergic reactions Orthostatic hypotension, especially in patients with severe renal insufficiency

^a For dose adjustments in patients with hepatic insufficiency, see [Appendix B, Table 10](#).

^b Also see [Table 17](#).

Key: CYP = cytochrome P; EFV = efavirenz; ETR = etravirine; MVC = maraviroc; NRTI = nucleoside reverse transcriptase inhibitor; NVP = nevirapine; PI = protease inhibitor; PO = orally; RAL = raltegravir; T-20 = enfuvirtide; TPV/r = tipranavir/ritonavir

Appendix B, Table 9. Characteristics of the CD4 Post-Attachment Inhibitor (Last updated December 18, 2019; last reviewed December 18, 2019)

Generic Name (Abbreviation) Trade Name	Formulation	Dosing Recommendations	Serum Half-Life	Elimination/Metabolic Pathway	Adverse Events
Ibalizumab (IBA) <i>Trogarzo</i>	Trogarzo: • Single-dose 2 mL vial containing 200 mg/1.33 mL (150 mg/mL) of ibalizumab	Trogarzo: • Administer a single loading dose of IBA 2,000 mg IV infusion over 30 minutes, followed by a maintenance dose of IBA 800 mg IV infusion over 15 minutes every 2 weeks. • See prescribing information for additional instructions for preparing, storing, and administering IBA, and for monitoring patients who are receiving IBA.	~64 hours	Not well defined	Diarrhea Dizziness Nausea Rash

Key: IBA = ibalizumab; IV = intravenous